Corticosteroid Regimen Delays Loss of Ambulation in Duchenne Muscular Dystrophy

muscular dystrophy
muscular dystrophy
A deflazacort regimen appeared to slow loss of ambulation, but not without several side effects.

Researchers aimed to perform an observational study of age at loss of independent ambulation (LoA) and side-effect profiles associated with different glucocorticoid corticosteroid (GC) regimens in Duchenne muscular dystrophy (DMD).

Luca Bello, MD, of the Children’s National Medical Center in Washington, D.C., and colleagues studied 340 participants in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG-DNHS). LoA was defined as continuous wheelchair use. Effects of prednisone or prednisolone (PRED)/deflazacort (DFZ), administration frequency, and dose were analyzed by time-varying Cox regression. Side-effect frequencies were compared using χ2 test.

READ FULL ARTICLE Curated publisher From